Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–55 of 55 matching trials from the live ClinicalTrials.gov search.
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Ultratrace Iobenguane I131
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
U.S. locations
3
States / cities
Iowa City, Iowa • Philadelphia, Pennsylvania • Houston, Texas
Conditions
Pheochromocytoma, Paraganglioma
Interventions
Ultratrace® Iobenguane I131
Radiation
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Iowa City, Iowa + 7 more
Conditions
Neuroendocrine Tumors
Interventions
3-[18F]Fluoro-para-hydroxyphenethylguanidine, [123I] metaiodobenzylguanidine, Positron emission tomography/computed tomography scan, Planar scintigraphy scan, Single photon emission computed tomography/computed tomography scan
Drug · Diagnostic Test
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Neuroendocrine Tumors, Heart Failure
Interventions
no carrier added metaiodobenzylguanidine
Drug
Lead sponsor
Bennett Chin
Other
Eligibility
21 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Adrenocortical Carcinoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Liver Cancer, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive, Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Retinoblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions
cixutumumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Months to 30 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
93
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more
Conditions
Heart Failure
Interventions
Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking
Drug · Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more
Conditions
Heart Failure, Congestive
Interventions
123I-mIBG (meta-iodobenzylguanidine)
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Princeton, New Jersey